KR840004944A - 미생물을 이용한 α- 및 β-인터페론의 제조방법 - Google Patents

미생물을 이용한 α- 및 β-인터페론의 제조방법 Download PDF

Info

Publication number
KR840004944A
KR840004944A KR1019830002362A KR830002362A KR840004944A KR 840004944 A KR840004944 A KR 840004944A KR 1019830002362 A KR1019830002362 A KR 1019830002362A KR 830002362 A KR830002362 A KR 830002362A KR 840004944 A KR840004944 A KR 840004944A
Authority
KR
South Korea
Prior art keywords
interferon
cdna
cells
rna
biosynthesis
Prior art date
Application number
KR1019830002362A
Other languages
English (en)
Other versions
KR920006349B1 (ko
Inventor
드브르킨-라슬(외 5) 에바
Original Assignee
요하네스 케크, 프리쯔 좀머
닥터 칼 토매 게젤샤프트 미트 베슈랭크터 하프퉁
프리쯔 좀머
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=6164725&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=KR840004944(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by 요하네스 케크, 프리쯔 좀머, 닥터 칼 토매 게젤샤프트 미트 베슈랭크터 하프퉁, 프리쯔 좀머 filed Critical 요하네스 케크, 프리쯔 좀머
Publication of KR840004944A publication Critical patent/KR840004944A/ko
Application granted granted Critical
Publication of KR920006349B1 publication Critical patent/KR920006349B1/ko

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1096—Processes for the isolation, preparation or purification of DNA or RNA cDNA Synthesis; Subtracted cDNA library construction, e.g. RT, RT-PCR
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/555—Interferons [IFN]
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S930/00—Peptide or protein sequence
    • Y10S930/01—Peptide or protein sequence
    • Y10S930/14—Lymphokine; related peptides
    • Y10S930/142—Interferon

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Saccharide Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

내용 없음

Description

미생물을 이용한 α- 및 β-인터페론의 제조방법
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음
제1도는 cDNA클론 뱅크(clone bank)의 제조 공정도.
제2도는 특이 트리데카뉴클레오타이드의 프리머의 사용에 의해 IFN-α 및 IFN-β-특이 DNA서열을 고농도로 함유하는 하이브리드화 샘플인 cDNA의 제조공정도.

Claims (9)

  1. 매트릭스로 적합한 RNA를 사용하여 합성한 cDNA로부터 클론뱅크를 제조하고, 이 클론뱅크중에서, 목적하는 유전자 생성물의 생합성을 위한 유전 정보를 함유하고 있는 클론을, 프리머로서 유전자 집단중에 저장된 올리고뉴클레오타이드를 사용하여 합성한 cDNA를 하이브리드화 샘플로 사용하거나, 올리고뉴클레오타이드 그 자체를 하이브리드화 샘플로 사용하여 식별하여, 식별된 클론을 배양하고 배양기간 중에 형성된 유전자 생성물을 분리함을 특징으로 하여, 두개 이상의 유전자(서로가 관련되지만 서로가 교차-하이브리드화할 필요는 없다)의 유전자 생성물을 동시에 제조하는 방법.
  2. 제1항에 있어서, 매트릭스로서 B-임파구 형태의 유도된 인가세포로부터 얻은 RNA를 사용하여 합성된 cDNA로부터 클론 뱅크를 제조하고, 이 클론 뱅크 중에서 α형 또는 β형 니터폐론의 생합성을 위한 유전 정보를 함유하는 클론을, 매트릭스로 인터페론 서열을 함유하는 RNA와 프리머로 인터페론-특이올리고뉴클레오타이드를 사용하여 합성된 cDNA를 하이브리드화 샘플로 사용하거나 올리고뉴클레오타이드 그 자체를 하이브리드화 샘플로 사용하여 식별하여, 식별된 클론을 배양하고 배양기간중에 형성된 유전자 생성물을 분리함을 특징으로 하여, α형 및 β인 터페론을 동시에 제조하는 방버.
  3. 제2항에 있어서, 트리데카뉴클레오타이드 5'dCCTTCTGGAACTG 3'가 인터폐론-특이 올리고뉴클레오타이드로 사용됨을 특징으로 하는 방법.
  4. 제2항 또는 3항에 있어서, B-임파구형 인간세포로 세포주 NC-37, 나말와, 아쿠바 또는 RPM1세포를 사용함을 특징으로 하는 방법.
  5. 제2항 또는 3항에 있어서, B-임파구형 인간세포로 나말와 세포를 사용함을 특징으로 하는 방법.
  6. 제2항 내지 5항중의 어느 하나에 있어서, α형 인터페론의 생합성을 코드화한 DNA-서열이 다음식의 부분서열을 함유하는 방법.
  7. 매트릭스로서 B-임파구 형태의 유도된 인간 세포로부터 얻은 RNA를 사용하여 합성한 cDNA로부터 클론 뱅크를 제조하고, 이어서 인터페론 서열을 함유하는 RNA를 매트릭스로 하고 인터페론-특이 올리고뉴클레오타이드를 프리머로 하여 합성한 cDNA를 하이브리드화 샘플로 사용하거나, 올리고뉴클레오타이드 그 자체를 하이브리드화 샘플로 사용하여 α형 또는 β형 인터페론의 생합성을 위한 유전 정보를 함유하는 클론을 식별하여 수득한 DNA-서열 중에 유정 정보를 함유하는 하이브리드 플라스미드를 사용하여 미생물, 바람직하게는에쉐리키아 콜리틀 형질 전환시킴을 특징으로 하여, 상술한 하이브리드 플라스미드 중에 제2항 내지 6항에서 청구한 α형 또는 β형 인터페론의 생합성을 위한 유전정보를 함유하는 미생물을 제조하는 방법.
  8. 제7항에서 정의한 하이브리드 플리스미드로부터 분리된, α형 또는 β형 인터페론의 아미노산 서열을 코드화하는 cDNA와 플라스미드, 바람직하게는 플라스미드 pBR322를 결합시킴을 특징으로하여, 제7항에서 정의한 하이브리드 플라스미드를 제조하는 방법.
  9. 인간 세포로부터 RNA를 얻고, 이들로부터 mRNA를 분리하여 이 mRNA를 사용해서 cDNA를 제조함을 특징으로하여, 제7항에서 정의한 하이브리드 플라스미드로부터 분리된, α형 또는 β형 인터페론의 아미노산 서열을 코드화하는 cDNA를 제조하는 방법.
    ※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.
KR1019830002362A 1982-05-28 1983-05-28 미생물을 이용한 α- 및 β-인터페론의 제조방법 KR920006349B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DEP3220116.8 1982-05-28
DE19823220116 DE3220116A1 (de) 1982-05-28 1982-05-28 Mikrobiologisch hergestellte (alpha)- und ss-interferone, dna-sequenzen, die fuer diese interferone codieren, mikroorganismen, die diese genetische information enthalten, und verfahren zu ihrer herstellung
DE3220116.8 1982-05-28

Publications (2)

Publication Number Publication Date
KR840004944A true KR840004944A (ko) 1984-10-31
KR920006349B1 KR920006349B1 (ko) 1992-08-03

Family

ID=6164725

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019830002362A KR920006349B1 (ko) 1982-05-28 1983-05-28 미생물을 이용한 α- 및 β-인터페론의 제조방법

Country Status (22)

Country Link
US (1) US4820638A (ko)
EP (1) EP0095702B1 (ko)
JP (2) JPH0774238B2 (ko)
KR (1) KR920006349B1 (ko)
AT (1) ATE42114T1 (ko)
AU (1) AU565479B2 (ko)
DD (1) DD211359C4 (ko)
DE (2) DE3220116A1 (ko)
DK (1) DK164742C (ko)
ES (2) ES522762A0 (ko)
FI (1) FI82072C (ko)
GR (1) GR79236B (ko)
HK (1) HK112893A (ko)
HU (1) HU196452B (ko)
IL (1) IL68790A (ko)
MX (1) MX9202815A (ko)
NO (1) NO168538C (ko)
NZ (1) NZ204384A (ko)
SG (1) SG38692G (ko)
SU (1) SU1346048A3 (ko)
UA (1) UA8037A1 (ko)
ZA (1) ZA833845B (ko)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3247922A1 (de) * 1982-12-24 1984-06-28 Boehringer Ingelheim International GmbH, 6507 Ingelheim Dna-sequenzen, deren herstellung, diese sequenzen enthaltende plasmide und deren verwendung zur synthese eukaryotischer genprodukte in prokaryoten
DE3515336C2 (de) * 1985-04-27 1994-01-20 Boehringer Ingelheim Int Verfahren zur Herstellung und Reinigung von â-Interferon
US4709324A (en) * 1985-11-27 1987-11-24 Motorola, Inc. Data processor control unit having an interrupt service using instruction prefetch redirection
CA2025180A1 (en) * 1989-10-12 1991-04-13 William G. Weisburg Nucleic acid probes and methods for detecting pathogenic candida yeasts
US6685933B1 (en) 1998-07-28 2004-02-03 The United States Of America As Represented By The Department Of Health And Human Services Interferon α hybrids
US20020197235A1 (en) * 2000-11-03 2002-12-26 Moran Stanford Mark Method for short-term and long-term drug dosimetry
FR2817559B1 (fr) * 2000-12-06 2003-12-12 Genodyssee Procede de determination d'un ou plusieurs polymorphisme(s) fontionnel(s) dans la sequence nucleique d'un gene "candidat" fonctionnel preselectionne et ses applications
FR2821625B1 (fr) * 2001-03-01 2003-05-16 Genodyssee Nouveaux polynucleotides comportant un polymorphisme de type snp fonctionnel dans la sequence nucleotidique du gene ifn-alpha-2 ainsi que de nouveaux polypeptides codes par ces polynucleotides et leurs utilisations therapeutiques
FR2823220B1 (fr) * 2001-04-04 2003-12-12 Genodyssee Nouveaux polynucleotides et polypeptides de l'erythropoietine (epo)
DE60237721D1 (de) * 2001-11-09 2010-10-28 Intarcia Therapeutics Inc Kombinationstherapie mit omega-interferon zur behandlung von hepatitis c virus oder gelbfieber virus infektionen
US20040063912A1 (en) * 2002-03-15 2004-04-01 The Brigham And Women's Hospital, Inc. Central airway administration for systemic delivery of therapeutics
WO2003099320A1 (en) 2002-05-24 2003-12-04 Zensun (Shanghai) Sci-Tech.Ltd Neuregulin based methods and compositions for treating viral myocarditis and dilated cardiomyopathy
DE60332358D1 (de) * 2002-09-09 2010-06-10 Hanall Pharmaceutical Co Ltd Protease-resistente modifizierte interferon alpha polypeptide
JP4889505B2 (ja) 2004-02-02 2012-03-07 アンブレツクス・インコーポレイテツド 被修飾されたヒト成長ホルモンポリペプチドおよびこれらの使用
US11246913B2 (en) 2005-02-03 2022-02-15 Intarcia Therapeutics, Inc. Suspension formulation comprising an insulinotropic peptide
WO2006083761A2 (en) 2005-02-03 2006-08-10 Alza Corporation Solvent/polymer solutions as suspension vehicles
ES2351527T3 (es) 2006-05-30 2011-02-07 Intarcia Therapeutics, Inc Modulador de flujo en dos piezas con conducto interno para un sistema osmótico de administración.
EP2359808B1 (en) 2006-08-09 2013-05-22 Intarcia Therapeutics, Inc Osmotic delivery systems and piston assemblies
US20080260820A1 (en) * 2007-04-19 2008-10-23 Gilles Borrelly Oral dosage formulations of protease-resistant polypeptides
EP2157967B1 (en) 2007-04-23 2013-01-16 Intarcia Therapeutics, Inc Suspension formulations of insulinotropic peptides and uses thereof
CA2726861C (en) 2008-02-13 2014-05-27 Intarcia Therapeutics, Inc. Devices, formulations, and methods for delivery of multiple beneficial agents
EP3323423B1 (en) 2009-09-28 2020-06-17 Intarcia Therapeutics, Inc Rapid establishment and/or termination of substantial steady-state drug delivery
US20120208755A1 (en) 2011-02-16 2012-08-16 Intarcia Therapeutics, Inc. Compositions, Devices and Methods of Use Thereof for the Treatment of Cancers
WO2013024158A1 (en) 2011-08-17 2013-02-21 INSERM (Institut National de la Santé et de la Recherche Médicale) Combinations of protein kinase inhibitors and interferons or of protein kinase inhibitors and direct acting antivirals for the treatment and the prevention of hcv infection
WO2013024156A2 (en) 2011-08-17 2013-02-21 INSERM (Institut National de la Santé et de la Recherche Médicale) Combinations of anti-hcv-entry factor antibodies and interferons for the treatment and the prevention of hcv infection
WO2014033266A1 (en) 2012-08-31 2014-03-06 INSERM (Institut National de la Santé et de la Recherche Médicale) Anti-sr-bi antibodies for the inhibition of hepatitis c virus infection
US9889085B1 (en) 2014-09-30 2018-02-13 Intarcia Therapeutics, Inc. Therapeutic methods for the treatment of diabetes and related conditions for patients with high baseline HbA1c
MA44390A (fr) 2015-06-03 2019-01-23 Intarcia Therapeutics Inc Systèmes de mise en place et de retrait d'implant
SG11201810102SA (en) 2016-05-16 2018-12-28 Intarcia Therapeutics Inc Glucagon-receptor selective polypeptides and methods of use thereof
USD860451S1 (en) 2016-06-02 2019-09-17 Intarcia Therapeutics, Inc. Implant removal tool
USD840030S1 (en) 2016-06-02 2019-02-05 Intarcia Therapeutics, Inc. Implant placement guide
CN110225762A (zh) 2017-01-03 2019-09-10 因塔西亚制药公司 包括glp-1受体激动剂的连续施用和药物的共同施用的方法

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2906160A1 (de) * 1979-02-17 1980-09-04 Thomae Gmbh Dr K Verbessertes verfahren zur herstellung von humaninterferon
AU538665B2 (en) * 1979-10-30 1984-08-23 Juridical Foundation, Japanese Foundation For Cancer Research Human interferon dna
IL58765A (en) * 1979-11-21 1986-09-30 Yeda Res & Dev Process for the production of essentially pure messenger rna of human fibroblast interferon and process for the production of interferon beta
US4530901A (en) * 1980-01-08 1985-07-23 Biogen N.V. Recombinant DNA molecules and their use in producing human interferon-like polypeptides
CA1341567C (en) * 1980-01-08 2008-02-19 Charles Weissmann Dna sequences, recombinant dna molecules and processes for producing human interferon - like polypeptides
GB2068970B (en) * 1980-02-06 1983-06-22 Searle & Co Recombinant dna technique for the preparation of a protein resembling human interferon
DE3005897A1 (de) * 1980-02-16 1981-09-03 Hoechst Ag, 6000 Frankfurt Genprodukt eines hoeheren organismus aus einem dieses gen enhtaltenden mikroorganismus
DE3005843A1 (de) * 1980-02-16 1981-09-10 Hoechst Ag, 6000 Frankfurt Genprodukt eines hoeheren organismus aus einem dieses gen enthaltenden mikroorganismus
ES8302778A1 (es) * 1980-11-10 1983-02-01 Genentech Inc Un procedimiento para producir un polipeptido antiviral.
DE3106982A1 (de) * 1981-02-25 1982-09-09 Dr. Karl Thomae Gmbh, 7950 Biberach "neues tridecadeoxynukleotid, verfahren zu seiner herstellung und verwendung"
IL63327A (en) * 1981-07-16 1985-11-29 Yeda Res & Dev Production of interferon beta1 and alpha-phage recombinants for its production in host bacteria
GB2108510B (en) * 1981-10-03 1984-12-12 Ciba Geigy Ag Dnas, recombinant dnas, hosts containing them, polypeptides and processes for the production thereof

Also Published As

Publication number Publication date
ES8403522A1 (es) 1984-03-16
DD211359A5 (de) 1984-07-11
JPH0774238B2 (ja) 1995-08-09
HU196452B (en) 1988-11-28
NO831903L (no) 1983-11-29
ES8500321A1 (es) 1984-10-01
FI82072C (fi) 1991-01-10
DE3220116C2 (ko) 1993-02-18
EP0095702A1 (de) 1983-12-07
UA8037A1 (uk) 1995-12-26
SU1346048A3 (ru) 1987-10-15
AU565479B2 (en) 1987-09-17
IL68790A0 (en) 1983-09-30
DD211359C4 (de) 1986-09-24
EP0095702B1 (de) 1989-04-12
NO168538B (no) 1991-11-25
ES529360A0 (es) 1984-10-01
FI831818L (fi) 1983-11-29
ES522762A0 (es) 1984-03-16
ATE42114T1 (de) 1989-04-15
DK164742C (da) 1992-12-28
DK164742B (da) 1992-08-10
JP2558422B2 (ja) 1996-11-27
FI831818A0 (fi) 1983-05-23
DE3220116A1 (de) 1983-12-01
MX9202815A (es) 1992-06-30
DK239383D0 (da) 1983-05-27
GR79236B (ko) 1984-10-22
NO168538C (no) 1992-03-04
IL68790A (en) 1991-06-10
US4820638A (en) 1989-04-11
FI82072B (fi) 1990-09-28
DE3379591D1 (en) 1989-05-18
SG38692G (en) 1992-09-04
JPS5925689A (ja) 1984-02-09
AU1504483A (en) 1983-12-01
NZ204384A (en) 1986-11-12
DK239383A (da) 1983-11-29
ZA833845B (en) 1985-01-30
KR920006349B1 (ko) 1992-08-03
JPH0678774A (ja) 1994-03-22
HK112893A (en) 1993-10-29

Similar Documents

Publication Publication Date Title
KR840004944A (ko) 미생물을 이용한 α- 및 β-인터페론의 제조방법
Glis̆in et al. Ribonucleic acid metabolism following fertilization in sea urchin eggs
Wu Adenovirus DNA-directed transcription of 5.5 S RNA in vitro.
Perry The nucleolus and the synthesis of ribosomes
Singer et al. The effect of secondary structure on the template activity of polyribonucleotides
Gartland et al. Two interconvertible forms of tryptophanyl sRNA in E. coli.
Kato Possible role of DNA synthesis in formation of sister chromatid exchanges
Perret et al. Relaxation of a transfer RNA specificity by removal of modified nucleotides
US4321365A (en) Oligonucleotides useful as adaptors in DNA cloning, adapted DNA molecules, and methods of preparing adaptors and adapted molecules
KR970707269A (ko) 코리네형 박테리아에서 유전자 발현을 조절하는 dna(dna which regulates gene expression in coryne-form bacteria)
Moldave Nucleic acids and protein biosynthesis
Honjo et al. Transcription of Xenopus chromatin by homologous ribonucleic acid polymerase. Aberrant synthesis of ribosomal and 5S ribonucleic acid
KR840002031A (ko) Dna, 재조합 dna, 이들을 갖는 숙주 및 폴리펩타이드를 제조하는 방법
Cox Macromolecular structure and properties of ribonucleic acids
Gonano et al. Transfer ribonucleic acids in rat liver and Morris 5123 minimal deviation hepatoma
Nierlich et al. Transfer RNA synthesis in vitro
FR2567540A1 (fr) Procede de preparation d'un interferon leucocytaire humain alpha-2
KUMAR et al. Initiation of DNA synthesis in HeLa cell-free system
Yamamoto et al. Heterogeneity in the 3'-terminal sequence of ribosomal 5S RNA synthesized by isolated HeLa cell nuclei in vitro
Schmutzler et al. Genes, variant genes, and pseudogenes of the human tRNAVal gene family are differentially expressed in HeLa cells and in human placenta
Margulies et al. Asymmetric template function of microbial deoxyribonucleic acids: transcription of messenger ribonucleic acid
Weinberg et al. Histone gene heterogeneity in the sea urchin Strongylocentrotus purpuratus
Laskey et al. Analysis of chromosome replication with eggs of Xenopus laevis
Lisco et al. A note on chromosomes of two species of tree shrews (Tupaiidae)
Nečas et al. Homeostasis in the culture of Chlamydomonas geitleri at nitrogen limitation

Legal Events

Date Code Title Description
A201 Request for examination
E601 Decision to refuse application
E902 Notification of reason for refusal
J2X1 Appeal (before the patent court)

Free format text: APPEAL AGAINST DECISION TO DECLINE REFUSAL

G160 Decision to publish patent application
E701 Decision to grant or registration of patent right
GRNT Written decision to grant
FPAY Annual fee payment

Payment date: 19970723

Year of fee payment: 6

LAPS Lapse due to unpaid annual fee